DDInter1266 DDInter1112
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Naproxen {u} (Compound) treats {v} (Disease) gout
gout {u} (Disease) is treated by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Naproxen {u} (Compound) palliates {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Naproxen {u} (Compound) binds {v} (Gene) SLCO1A2
SLCO1A2 {u} (Gene) is bound by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Naproxen {u} (Compound) palliates {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is palliated by {v} (Compound) Gabapentin
Gabapentin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Naproxen {u} (Compound) causes {v} (Side Effect) Papilloedema
Papilloedema {u} (Side Effect) is caused by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Naproxen {u} (Compound) treats {v} (Disease) gout
gout {u} (Disease) is palliated by {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magaldrate
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticlopidine
Ticlopidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Naproxen (Compound) treats gout (Disease) and gout (Disease) is treated by Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Naproxen (Compound) palliates systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Naproxen (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Naproxen (Compound) palliates systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is palliated by Gabapentin (Compound) and Gabapentin may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Naproxen (Compound) causes Papilloedema (Side Effect) and Papilloedema (Side Effect) is caused by Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Naproxen (Compound) treats gout (Disease) and gout (Disease) is palliated by Acetylsalicylic acid (Compound) and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Magaldrate